Latest Financial Health News

Bulletin Resources continues its appeal against the refusal of a Native Vegetation Clearing Permit critical to advancing drilling at its Ravensthorpe Lithium Project, while maintaining a strong cash position and reviewing strategic opportunities.

K2 Asset Management has appointed longtime executive Hollie Wight as CEO, signaling a strategic push towards sustained profitability and diversified revenue growth in 2025.

Magnis Energy Technologies reveals that its partners IM3NY LLC and Imperium3 New York Inc have entered Chapter 11 bankruptcy proceedings, raising questions about future operations and financial stability.

PARKD Ltd reports substantial structural completions on flagship projects and positive operating cash flow in Q2 FY25, setting the stage for licensing negotiations with Fielders.

Cooper Metals reports promising exploration progress at its Mt Isa East copper-gold project and high-grade gold assays at the Gooroo project, while maintaining a solid cash reserve of $2.1 million.

Resonance Health has reported record quarterly customer receipts of $5 million, a 57% increase from the previous quarter, alongside a major $13.8 million clinical trial contract win, signaling robust growth across its healthcare technology and clinical trial services.

Hydrix Limited reports back-to-back profitable quarters driven by strong margins and cost efficiencies, underpinned by a robust $40 million sales opportunity pipeline in cardiac and medtech sectors.

Killi Resources reports compelling drill results from its Kaa gold-copper prospect in Queensland, confirming a large mineralised system and maintaining a strong cash position of $2.03 million to fund ongoing exploration.

De.mem Limited has delivered its second highest quarterly cash receipts ever alongside positive operating cash flow for the December 2024 quarter, marking a milestone full-year cash flow turnaround and setting the stage for continued growth in 2025.

Sprintex has locked in A$30 million in distribution agreements across the UK, Turkiye, and India, while advancing its innovative G25 Jet Blower launch, signaling a strong growth trajectory in energy-efficient technologies.

Dimerix Limited has inked a lucrative licensing agreement with Fuso Pharmaceutical for its kidney disease drug DMX-200 in Japan, while completing recruitment for its pivotal Phase 3 ACTION3 trial.

Ardea Resources reports robust financial health and significant progress on its Kalgoorlie Nickel Project’s Definitive Feasibility Study, fully funded by a Japanese consortium. The company strengthens its leadership and advances ESG-aligned development of a globally significant nickel-cobalt resource.